Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.1% on Wednesday.

Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast

Eli Lilly's eyewatering upsurge this year was upended by its double-slashed full-year 2024 guidance following the Q3 earnings update this morning. The slight Q3 revenue miss continues to highlight volatile supply chain dynamics facing its best-selling Zepbound/Mounjaro tirzepatide products. Investors were also caught off guard by the unprecedentedly material acquired IPR&D charge related to LLY's acquisition of Morphic Holdings in Q3.

What You May Have Missed From Eli Lilly's Q3 2024 Earnings Disappointment

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespread shortages in the U.S. The drugmaker blamed the misses on drug wholesalers cutting inventory of Zepbound and Mounjaro.

Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still fell short

Eli Lilly had $11.4 billion in revenue for the quarter (up 20% versus Q3 figures from last year), with a net income of $970 million after expenses. Analysts at the various Wall Street firms expected Lilly to have brought in about $12.2 billion. And if you look at the sales figures for the company's GLP-1 drugs, you see a shortfall there. Lilly's stock took quite a notable hit after these results were released. The Street loves increasing earnings and hates downside misses and uncertainty, and Lilly offered up both of those.

Taking A Look At Eli Lilly's Q3 2024 Revenue Miss Amid Supply Chain Challenges

Eli Lilly misses third-quarter estimates for earnings and sales. Mounjaro and Zepbound sales also miss estimates.

Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was a great investment — mostly due to the success of Mounjaro and Zepbound. Nevertheless, the stock seems expensive — also when compared to Novo Nordisk — and we should be very cautious about an investment.

Eli Lilly: The Stock Might Have Peaked

The big pharmaceutical company provided a disappointing Q3 update.

Why Eli Lilly Stock Is Sinking Today

While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Lilly (LLY) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Drug maker Eli Lilly's share price plunged Wednesday morning after the company reported worse third-quarter results than expected, especially in its weight-loss drug division, registering a rare misstep for the Wall Street darling.

Eli Lilly Stock Dives Toward Worst Day Since 2000 On Disappointing Earnings, Zepbound Sales

Eli Lilly and Co (NYSE:LLY) shares fell over 12% on Wednesday after the drug maker slashed guidance for the year following underwhelming figures for the third quarter. Sales of Eli's blockbuster weight loss drug Zepbound fell short of analysts' expectations, at $1.26 billion compared to estimates for $1.76 billion.

Eli Lilly tumbles as weight loss drug sales underwhelm, guidance slashed

Eli Lilly (LLY) came out with quarterly earnings of $1.18 per share, missing the Zacks Consensus Estimate of $1.52 per share. This compares to earnings of $0.10 per share a year ago.

Eli Lilly (LLY) Lags Q3 Earnings and Revenue Estimates

Eli Lilly's stock heads for biggest selloff since 2008 after sales of anti-obesity drugs Mounjaro and Zepbound came up well short of forecasts.

Eli Lilly's stock tumbles as Mounjaro, Zepbound sales miss by wide margins

Eli Lilly (LLY) shares tumbled 10% after its third-quarter results fell well short of analysts' estimates before the bell Wednesday.

Eli Lilly Stock Tumbles as Q3 Sales, Profits Fall Well Short of Estimates

Eli Lilly earnings and revenue missed Q3 views, with sales light for its diabetes and weight-loss drugs. Eli Lilly stock dived Wednesday.

Eli Lilly Dives On Earnings Miss As Diabetes, Weight-Loss Drugs Fall Short

Eli Lilly reported third-quarter adjusted profit and revenue that missed expectations, sending its stock tumbling roughly 10% Skyrocketing demand for injectable weight loss and diabetes drugs has forced both Eli Lilly and its main rival, Novo Nordisk, to invest billions to increase manufacturing capacity.

Eli Lilly stock tumbles 10% after missing estimates and slashing profit guidance

Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, even as demand for its weight-loss drug soared, hurt by higher manufacturing and acquisition-related costs.

Eli Lilly misses third-quarter profit amid soaring demand for weight-loss drug

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue from the olanzapine portfolio, total revenue increased 42%, and non-incretin revenue increased 17%.

Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products

Eli Lilly has a number of lucrative opportunities that should serve as tailwinds for sustained growth.

A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years

Eli Lilly has been a huge winner with its GLP-1 drugs.

Is Eli Lilly Stock a Buy?

Shares are up more than 50% already this year, as the story surrounding the company's GLP-1 drugs gets better and better.

Eli Lilly Reports Earnings Wednesday. It's All About Zepbound.

Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines, Mounjaro and Zepbound.

Can Mounjaro, Zepbound Help Eli Lilly Top Earnings Estimates Again?

Allstate

Advanced Micro Devices

Amazon

Amphenol

Dayforce Inc

DuPont de Nemours

First Solar

General Electric

Microsoft

Norwegian Cruise Line

Seagate Technology Holdings PLC

TransDigm

Uber

Zebra Technologies

BlackRock CEO Larry Fink says companies' earnings are “catching up” to high P/E ratios for their stocks. Here are 10 companies to keep an eye on.

Why these 17 stocks in the S&P 500 are now more compelling

Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients experiencing potentially serious brain swelling, according to interim results of a late-stage trial presented at a medical meeting on Tuesday.

Gradual dosing of Lilly Alzheimer's drug cuts brain-swelling risk, study finds

A change in the initiation of donanemab dosing, shifting one vial of donanemab from the first infusion to the third infusion, lowered ARIA-E to 14% compared to 24% in patients receiving the standard dosing regimen used in the pivotal Phase 3 clinical trial Reduction of amyloid plaque and P-tau217 on this modified titration was comparable to patients receiving the standard dosing regimen Lilly intends to submit this data to global regulators for a potential label update for Kisunla (donanemab-azbt) INDIANAPOLIS , Oct. 29, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive results from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a reduction in amyloid-related imaging abnormalities with edema/effusion (ARIA-E) at the 24-week primary endpoint for people receiving a slightly modified titration of donanemab in adults with early symptomatic Alzheimer's disease (AD).1 Donanemab is approved under the brand name Kisunla™ in the United States, Japan, Great Britain and other countries. These data were presented at the 17th Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain.

Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study

Eli Lilly and Co LLY will be reporting its third-quarter earnings on Wednesday. Wall Street expects $1.45 in EPS and $12.10 billion in revenues as the company reports at 10 a.m.

News for Eli Lilly Stock (LLY)